BIOBRAN MGN-3

Clinical Indication

Adjuvant to cancer treatment

Comments

Cancer Research UK statement

Do not prescribe

Drugs not recommended for use in LLR because of lack of evidence of clinical effectiveness, cost prioritization or concerns over safety